News | Structural Heart | March 24, 2022

HLT, Inc. Gains FDA Approval for Two TAVR Clinical Studies

The studies will assess the performance of its HLT Meridian TAVR Valve System to treat aortic stenosis and aortic regurgitation for high-risk patients suffering from aortic disease

HLT Inc., a Bracco Group Company and a leader in the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, announced today that it has received U.S. Food and Drug Administration (FDA) approval for two clinical studies to assess the performance and safety of its HLT Meridian TAVR Valve System to treat aortic stenosis and aortic regurgitation among high-risk patients suffering from aortic disease.

March 24, 2022 — HLT Inc., a Bracco Group Company and a leader in the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, announced today that it has received U.S. Food and Drug Administration (FDA) approval for two clinical studies to assess the performance and safety of its HLT Meridian TAVR Valve System to treat aortic stenosis and aortic regurgitation among high-risk patients suffering from aortic disease.

“We are thrilled to be providing a minimally invasive option to patients suffering from aortic disease,” said David R. Elizondo, President and CEO of HLT. “Currently, there are treatments available that focus specifically on aortic stenosis. The HLT technology has been designed to treat a much broader segment in aortic disease where currently treatment options are limited. The HLT Meridian TAVR Valve System is designed to address both patients’ and physicians’ needs that are unmet by current offerings, and is intended to expand and optimize the clinical and procedural performance.”

Aortic stenosis, a narrowing of the aortic valve that obstructs blood flow from the heart, is one of the most common heart valve diseases. Approximately 250,000 people in the U.S. are diagnosed annually with symptomatic severe aortic stenosis (SSAS). Aortic regurgitation is when an aortic valve does not close properly, resulting in reverse blood flow from the aorta back into the left ventricle. Surgical aortic valve replacement (SAVR) is the current standard treatment for these patients. However, TAVR is a minimally invasive way to replace the diseased aortic valve without open heart surgery for this patient population.

Dr. Satya Shreenivas, Chief Medical Officer at HLT and experienced interventional cardiologist with an expertise in the care of patients with structural heart disease, added, “The HLT platform is exciting because its new single operator delivery system and unique valve design offer the promise of a more accurate, and thus possibly less complicated procedure, and better long-term outcomes due to the intended reduced stress on the individual valve leaflets. In addition, the delivery system is designed to allow precision in valve delivery. This, combined with the radial strength of the valve, are expected to be a great combination to treat non-calcified aortic annuli that are frequently seen in aortic regurgitation.”

Current TAVR options require multiple operators for deployment, do not allow for complete repositioning or assessment prior to implant and cannot treat expanded indications, such as aortic regurgitation. Furthermore, the patients are left with concerning rates of adverse events such as the need for permanent pacemaker implantation, paravalvular leakage, and patient-prosthesis mismatch, all of which cause concern. Unlike current TAVR solutions, the HLT Meridian TAVR Valve System is designed to have the benefits of both balloon expandable and self-expanding platforms with a lower profile and non-obstructive design that reduces coronary and conduction obstruction. Its design for increased hemodynamic performance is expected to reduce the concern of patient-prosthesis mismatch. It has a unique design as the only TAVR valve with an isolated valve structure where the leaflets are not attached to an annular structure. The novel design is intended to reduce tissue stress, improve long-term durability, minimize leakage and minimize ventricular exposure.

As stated above, the HLT Meridian TAVR Valve System is not yet cleared/ approved by FDA. It is pending clinical investigation and will be reviewed for clearance/approval in the future.

For more information: www.hltmedical.com

Find more structural heart technology news


Related Content

News | Structural Heart

June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program, reinforcing the positive ...

Home June 07, 2024
Home
News | Structural Heart

April 25, 2024 — Atlantic Health System’s Morristown Medical Center treated the first patient in New Jersey using ...

Home April 25, 2024
Home
News | Structural Heart

April 9, 2024 — UC Davis Health cardiology team members are among the first in the country to treat patients with ...

Home April 09, 2024
Home
News | Structural Heart

March 25, 2024 — In a groundbreaking medical advancement, three esteemed cardiologists from CLS Health, Dr. Bahaeddin ...

Home March 25, 2024
Home
News | Structural Heart

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

Home March 12, 2024
Home
News | Structural Heart

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
News | Structural Heart

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

Home February 15, 2024
Home
News | Structural Heart

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

Home February 09, 2024
Home
News | Structural Heart

January 4, 2024 — Laguna Tech USA, a privately-held medical technology company dedicated to innovations in structural ...

Home January 04, 2024
Home
News | Structural Heart

December 12, 2023 — Think of them as the Energizer Bunnies of the heart, tiny natural batteries that keep this vital ...

Home December 12, 2023
Home
Subscribe Now